HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
We now rank 3rd in pharmaceutical production by volume and 14th by value
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
CSPC will receive an upfront payment of $100 million from AstraZeneca
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
Pfizer's decision is based on the totality of clinical data
Subscribe To Our Newsletter & Stay Updated
